LITMUS Molecular Design (LMD)creates and characterizes new molecular entities.

LMD's technology, LITMUS Spectral Modeling, is a patented method of accurately predicting a molecule's:

• Chemical reactivity
• Biological activity
• Receptor binding affinity
• Toxicity, carcinogenicity
• Metabolism
• Absorption/through-membrane transmission,
• and chemical and physical properties,

based upon spectral information.

Developed at FDA's National Center for Toxicological Research (NCTR), LITMUS Spectral Modeling represents a "disruptive" technology which produces significantly more accurate results than Quantitative Structure Activity Relationships (QSAR) and Combinatorial Chemistry/High-Throughput Screening; currently the two most widely used methodologies. In side by side tests, LITMUS Spectral Modeling’s predictive accuracy proved to be 80-96% compared to 30-60% predictive accuracy for QSAR. 

LITMUS Molecular Design’s value proposition is to enable pharmaceutical companies, chemical manufacturers, and herbicide and pesticide manufacturers to:

• Identify promising new compounds
• Predict efficacy or toxicity of new compounds
• Modify existing compounds to be more effective/less toxic
• Expedite introduction of drugs/NCEs
• Reduce time/cost of new drug/chemical development significantly

INNOVATE. NOT RENOVATE.